



(51) International Patent Classification:
A61L 2/14 (2006.01)

(21) International Application Number:

PCT/IB2010/001439

(22) International Filing Date:

15 June 2010 (15.06.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/187,340

16 June 2009 (16.06.2009)

US

(71) Applicant (for all designated States except US):
PLASMEDICA TECHNOLOGIES LIMITED [IE/IE];
Unit 5 Middleton Enterprise Centre, Owenacurra Business
Park, Middleton, Cork (IE).

(71) Applicant (for ZW only): **HANLEY, Patrick** [US/US];
1162 Fassler Avenue, Pacifica, CA 94111 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **O'KEEFFE, Joe**
[IE/IE]; 15 Dunthane Park, Fermoy, Co Cork (IE). **DOB-**
BYN, Peter [IE/IE]; Highrange, Rostellan, Middleton, Co

Cork (IE). **O'DONOGHUE, John** [IE/IE]; 5 Sallybrook,
Abbeyside, Dungarvan, Co Waterford (IE). **O'NEILL,**
Liam [IE/IE]; Clonmult, Middleton, Co Cork (IE).

(74) Agents: **BOYCE, Conor** et al.; FRKelly, 27 Clyde Road,
Ballsbridge, Dublin 4 (IE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK,

[Continued on next page]

(54) Title: WOUND HEALING DEVICE




Figure 1

(57) Abstract: A plasma coating device for treating a wound comprises a plasma chamber having: one or more electrodes, a gas supply inlet, a plasma outlet exposed to ambient pressure, and an ignition system operatively connected to the electrodes for providing a non-thermal equilibrium plasma within the plasma chamber. An aerosol delivery system is operable to introduce a bioresorbable material as an aerosol into the plasma, to produce a coating on the wound surface.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, —
GW, ML, MR, NE, SN, TD, TG).

*before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

Published:

— *with international search report (Art. 21(3))*

Wound Healing Device

Background

5 Electrical plasma devices are well established in medicine. For example, Massarweh et al, J. Am. Coll. Surg., 2006, 202 (3), 520, discloses plasma devices for surgery; Reich et al, *European Urology*, 2003, 44 (2), 272-276, describe the use of an argon plasma (APC) to coagulate blood and stop bleeding; and Mennel et al, *Experimental and Toxicological Pathology*, 2002, 54 (3), 255, disclose using a helium plasma to obtain a similar response
10 to the APC technique.

Plasmas can also be used to sterilise skin as disclosed in G. Fridman, A.D. Brooks, M. Balasubramanian, A. Fridman, A. Gustol, V.N. Vasilets, H. Ayan, G. Friedman, *Plasma Process. Polym.* 4 (2007) 370) and WO2006/116252. The use of plasma devices to promote
15 wound healing has also been disclosed in US2008/0237484 and in WO2009/101143.

Outside of medicine, plasma devices are widely used to produce thin film coatings in industrial applications. Plasma polymers offer a number of advantages over conventional polymer coatings. The combination of reactive plasma and chemically active monomers
20 produces a coating that is uniform, pin hole free and well bonded to the substrate. Furthermore, the curing can occur in a manner that is almost instantaneous, offering numerous processing advantages.

US 4,929,319 describes a method for depositing a polymer coating in which an aerosol is
25 introduced into a corona plasma and the reactive species thereby generated are allowed to deposit in a substrate that is also brought into the corona plasma.

WO 02/28548 describes a process in which an aerosol is introduced into an atmospheric pressure glow discharge (APGD) plasma and a coating is thereby formed on a substrate.
30 The coating chemistry was found to be virtually unchanged from that of the precursor molecules by the exposure to the homogeneous APGD plasma.

WO2005/106477 describes a process for coating a substrate with a biomolecule in which the substrate is placed between two electrodes and a plasma is generated by applying an alternating current in which a positive voltage is applied to the first electrode and a zero voltage to the second electrode, and then a zero voltage to the first electrode and a negative voltage to the second electrode. A coating is then applied by introducing a reactive precursor to form a coating and biomolecules are simultaneously immobilised. The biomolecules may be introduced as an aerosol.

WO 05/110626 discloses coating a substrate with a polymer layer containing active agents. The method involves exposing a mixture of polymer forming materials (which react to form chemical bonds in a plasma) and active agents (which do significantly react in the plasma) to plasma. The polymer forming materials listed include various acrylates, alkenes and dienes that can be polymerised by the reactive species present within a plasma.

These prior documents rely on the plasma to induce the polymerisation of a monomer to produce the thin film or coating. The polymerisation can be driven through free radical (A. Bogaerts et al., *Spectrochimica Acta Part B*, 57 (2002) 609–658) or cationic reaction mechanisms (Daniel C. Guerin, David D. Hinshelwood, Sorin Monolache, Ferencz S. Denes, and Vasgen A. Shamamian, *Langmuir*, **2002**, 18 (10), pp 4118–4123).

Thus, while the methods described in WO 05/106477 and WO 05/110626 do allow for the deposition of polymers containing active agents, they are reliant upon the presence of a precursor which can react in the plasma to form the polymer coating during the deposition process. The requirement to induce reactions within the polymer precursor without damaging the active agent limits the degree of polymerisation that can be achieved.

Summary of the Invention

The present invention provides a plasma device as claimed in claim 1.

In a further aspect, there is provided a non-thermal plasma treated bioresorbable material for use in coating a wound as claimed in claim 14.

In a still further aspect there is provided a method of treating a wound according to claim 22.

- 5 In embodiments of the present invention, a non-thermal plasma is applied to a wound. The plasma can sterilise the area, coagulate blood and deposit a bioresorbable coating to seal the wound area. The coating can further include active compounds to aid in wound healing.
- 10 The bioresorbable material can include blood plasma, chitosan or collagen, but may alternatively or in addition include a protein, a biopolymer (such as chitin, alginates, cellulose or hyaluronan), or a synthetic biodegradable polymer (such as poly (lactic-co-glycolic acid) (PLGA), polylactic acid, polycaprolactone, polyglactin) or a mixture of such materials.
- 15 Preferably, the bioresorbable material is introduced into a non-thermal plasma as a precursor in the form of an aerosol. The bioresorbable material pre-cursor can either be dissolved or dispersed in a suitable carrier liquid.
- 20 Preferably, the active compound, for example, drug, enzyme, cell, protein or DNA may be either introduced into the plasma dissolved in the bioresorbable material pre-cursor or introduced separately.

In such implementations, the active compound is incorporated alongside a pre-polymerised polymer which allows the polymerisation and film forming steps to be separated out and provides a greater degree of process control.

The mixture of bioresorbable material, active compound and plasma further interact to produce a coating on the wound surface. The wound can either directly contact the plasma or can be placed downstream of the plasma chamber outlet.

In one embodiment, blood constituents are nebulised into the plasma, to deposit a layer of coagulated blood or blood plasma onto a wound surface.

Brief Description of the Drawings

Embodiments of the invention will now be described, by way of example, with reference
5 to the accompanying drawing, in which:

Figure 1 is a schematic view of a plasma device in accordance with an embodiment of the present invention.

10 Description of the Preferred Embodiments

Referring now to Figure 1, there is shown a schematic view of a plasma device according to an embodiment of the invention. The device includes a plasma chamber 1 including a metal electrode 6 to which a high voltage power supply / ignition system 2 is operatively
15 connected. The chamber 1 further includes a gas inlet port 3 through which a supply of gas, for example, helium, argon or nitrogen or mixtures thereof is fed in operation of the device and which in combination with the ignition system causes a plasma to be struck and to stream from an outlet 8 of the plasma chamber. In the illustrated embodiment, a liquid delivery system 4 is operatively connected to an inlet of the plasma chamber and an
20 internal nebuliser 5 causes the supplied liquid to be sprayed into the chamber 1 as an aerosol. In alternative embodiments, not shown, an external nebuliser feeds the aerosol to a region outside the plasma chamber where it interacts with the reactive species emanating from the outlet 8 of the plasma chamber before coating a wound over which the plasma device is being passed.

25 In embodiments of the present invention, the plasma device initially sterilises and coagulates the wound. Then, by providing an aerosol from the supply 4 containing a bioresorbable material which may also contain an active agent, and introducing that aerosol into a plasma chamber 1, or into the reactive species that exist downstream of the
30 plasma chamber 1, the device produces a coating on the wound. If required, the sterilisation, coagulation and coating deposition can occur simultaneously. Deposition of such a coating enables the continuous interaction of the pro-healing materials with the

wound and provides for enhanced wound healing. Furthermore, the coating seals the wound and limits the opportunity for further bacteria to infect the wound site.

The term wound can be taken to encompass all forms of damage to the skin or body including burns, cuts, tears, piercings, contusions, abrasions, lacerations, punctures, gun shots or other forms of injury to the body. It may also encompass infections or chronic wounds such as ulcers.

The invention described herein allows the introduction of bioresorbable material including: proteins such as collagen, fibrin or fibronectin; biopolymers such as hyaluronan, chitosan, alginates and cellulose; and also biodegradable synthetic polymers such as PLGA which do not form using the same vinyl polymerisation reactions favoured by conventional plasma reactions onto a wound site. The plasma may cross-link these materials to produce a dry coating, but the degree of cross-linking is limited and is not sufficient to alter the functionality of the deposited material.

Embodiments of the present invention employ non-thermal plasma devices where the plasma operates close to room temperature thus allowing the processing of temperature sensitive materials, without imposing a damaging thermal burden onto the material. Nonetheless, the hot electrons of the plasma create, through high-energy collisions, a rich source of radicals and excited species with a high chemical potential energy capable of chemical and physical reactivity. Non-thermal equilibrium plasmas can be created at ambient pressure and have been reviewed extensively by Roth (Roth J.R., Industrial Plasma Engineering, Volume 2 Applications to Non-thermal Plasma Processing, Institute of Physics Publishing, 2001, pages 37-73). Such plasmas include dielectric barrier discharges. Another non-thermal equilibrium plasma is the Atmospheric pressure glow discharge (APGD) as described by Okazaki et al (J. Phys. D: Appl. Phys., 26, 889-892 (1993)). These APGD plasmas have been described extensively by Roth as One Atmosphere Uniform Glow Discharge Plasmas (OUAGDP) and are found to operate from 0.5 to 40 kHz. Corona plasma devices can also operate in non-thermal equilibrium mode. Various plasma jets are also capable of operating in a "cold" or non-thermal equilibrium mode.

Embodiments of the present invention employ plasma devices operating at frequencies above 100 kHz, which is beyond the sensory threshold of a patient's nervous system. For optimum control, the plasma is operated below 500 kHz and may be pulsed on and off in a controlled fashion to minimise the energy delivered to the aerosol and patient. This enables controlled plasma reactions that preserve precursor functionality and do not damage or fragment sensitive active species.

Alternatively, the plasma can be contained between two electrodes, with a grounded electrode separating the person or object to be treated from the plasma, such that no significant voltage is applied to any object or person placed downstream of the device. This can be accomplished using a plasma device such as described by Ladwig et al (Surface & Coatings Technology 201 (2007) 6460–6464). Use of such a plasma device would allow the plasma to operate at frequencies below 100 kHz.

The plasma parameters (electrode design, frequency, voltage, gas composition, etc.) can be chosen to control the plasma process and ensure that the plasma operates in a non-thermal manner to produce a low-temperature plasma, which does not adversely affect temperature sensitive materials which are being deposited.

Furthermore, the precursor can be introduced downstream of the plasma chamber outlet to minimise damage to the coating forming materials. This allows coatings containing materials sensitive to temperature, ions, free radicals and other active species present in the plasma to be deposited where they would otherwise be damaged if introduced directly into the plasma chamber.

Various active compounds can be incorporated into the coating produced by this device. These can include anti-cancer drugs, anti-inflammatory drugs, immuno-suppressants, antibiotics, antimicrobials, heparin, a functional protein, a regulatory protein, structural proteins, oligo-peptides, antigenic peptides, nucleic acids, immunogens, glycosaminoglycans and combinations thereof.

Other active compounds include polypeptides, polyglycans, hormones, lipids, interferons, cartilage, therapeutic biologic agents both cellular and synthetically derived, autologous,

homologous and allographic and xenographic biologic agents, autologous or homologous, recombinant and synthetic derived blood cells and products containing antimicrobial/antibiotic agents, bacteriostatic agents, stem cells, stromal cells; fibroblast derived Human Dermal Collagen, matrix proteins, growth factors and cytokines, fibronectin, cells found in loose connective tissue such as endothelial cells, cells found in adipose tissue, macrophages/monocytes, adipocytes, pericytes, reticular cells found in bone marrow stroma and cultured autologous keratinocytes.

In a preferred application, the wound is coated with a layer of either coagulated blood or blood extracts. The coating is produced by nebulising a supply of blood, or blood constituents, into the plasma chamber or into the species exiting from the plasma chamber. This offers a route to producing thin films, which are highly biocompatible and already contain the necessary factors (fibrin, cytokines, etc.) necessary to seal the wound and to induce wound healing.

Nonetheless, the nature of the deposited layer may be varied dependent on factors including: the underlying cause of the wound, the characteristics of the wound, the stage of wound healing, the particular patient needs and risk factors, availability of autologous materials.

Thus, different depositions can be used depending on whether wound healing is at the haemostasis, inflammation, proliferation/granulation or maturation/remodelling phase. Examples of materials for the various phases of wound healing include:

1. Fresh trauma/burns: Seal/contain wound with a temporary resorbable material containing appropriate active agents including, for example, antimicrobials, analgesics, vasoconstrictors in order to contain the wound while minimising dehydration/shock, pain, blood loss, risk of infection/contamination, further tissue loss, etc and initiating haemostasis.
2. Haemostasis stage: A resorbable material such as blood plasma or platelets including active agent(s) such as, vasoconstrictors, adenosine diphosphate (ADP), thrombin, fibrinogen/fibrin, cytokines (PDGF), chemotactic factors, chemocines or coagulation factors.

3. Inflammation stage: A resorbable material such as blood plasma including, for example, neutrophils, monocytes, phagocytes, mast cells, proteolytic enzymes, leukocytes.
4. Proliferation/granulation stage: A resorbable material including for:
 - 5 a. Granulation – macrophages, Fibroblastic Growth Factor (FGF), Epidermal Growth Factor (EGF), transforming growth factor beta (TGF-beta), Extra cellular matrix (ECM), fibroblasts, myofibroblasts
 - b. Contracture - fibroblasts, collagen, endothelial cells, keratinocytes, angiocytes, neurocytes,
 - 10 c. Epithelisation - growth factors, fibrin, collagen, and fibronectin
5. Maturation/remodelling: Type I collagen.
6. Enhanced/accelerated wound healing or for large wound and burn injuries or chronic non-healing ulcers: Cytokines and growth factors
- 15 Other applications including cornea regeneration using cytokines following abrasion or cataract treatment.

All variants may also provide the following:

- A moisture retaining occlusive barrier and high humidity at the wound surface;
- 20 Gaseous exchange;
- Thermal insulation; and
- Protection against secondary infection

Examples:

25

1. Deposition of blood plasma coating

A biocompatible coating was deposited on to a glass slide using a non-thermal plasma discharge and blood plasma as the precursor. The plasma discharge was created by
30 applying an alternating voltage to a corona needle electrode assembly within a dielectric housing. The voltage was applied at a frequency of 100 kHz from a Redline G2000 high voltage power supply. Helium was used as a ballast gas at a flow rate of 14 litres/minute. (It will be appreciated that other gases including argon or nitrogen or mixtures thereof

could also be used.) The blood plasma extract was nebulised into the plasma using a Burgener pneumatic nebuliser (Burgener Research, Canada) at a flow rate of 51 microlitres/min. The input power was applied using a 45% duty cycle (ratio of time on to time off) and a selected input power on the power supply of 107 V. This corresponded to an actual applied voltage of 12.7 kV (pk-pk) applied to the electrodes. The substrate was a glass slide placed approximately 5 mm downstream of the plasma exit.

The blood plasma was sprayed through the plasma and landed upon the glass slide, where it coagulated instantly to form a coating. After deposition, the coating was inspected at a magnification of 40X and the viable cell numbers were counted. Prior to being exposed to the electrical discharge, cell viability was estimated to be 90%. After undergoing nebulisation and plasma coagulation, over 70% of the cells were still deemed viable, indicating that biological materials have been successfully deposited intact and capable of participating in a biological healing process.

2. Deposition of a biopolymer (chitosan)

Chitson is known to have antimicrobial properties and is also a common scaffold material used in regenerative medicine. Water-soluble chitosan was dissolved in deionised water to give a concentration of 20 mg/ml. This liquid was introduced at 50 μ L/min into the equipment described in Example 1 and coatings were deposited onto glass slides. Coatings were deposited at a power input setting of 170V and 150 kHz and for times of 45 seconds, 1 minute and 3 minutes. In each case, a clear coating was detected on the surface of the glass slide. This coating was not removed by wiping with a tissue, indicating that the coating was dry, cured and adherent.

3. Deposition of a protein solution (collagen) at low frequency

Collagen is a known aid in wound healing process and is a key component of skin. A plasma device comprising a needle corona electrode powered by a 100W Plasma Technics Inc power supply operating at c. 20 kHz was provided. Helium was introduced to the system at a rate of 8 litres/minute. An acidified solution of collagen (3.8 mg/ml) was nebulised into the resultant discharge at a flow rate of 50 μ L/min and coatings were

deposited onto glass slides for 1 – 2 minutes. All deposits were found to be coherent, dry and adhered well to the substrate, indicating that a cured coating had been formed.

4. Deposition of a protein solution (collagen) at high frequency

5

A solution of collagen (1 mg/ml) was introduced into the equipment described in Example 1. The plasma was operated at 115V input power, 148 kHz and a duty cycle of 44%. Helium was introduced at a rate of 5 litres/min. The collagen solution was introduced at a rate of 50 μ L/min and a coating was deposited onto polished Si wafers for either one minute or two minutes. Ellipsometry detected a coating with a thickness of 50 nm for the one minute sample and 140 nm for the two minute sample, confirming that a coating had been deposited.

10

Claims:

1. A plasma coating device for treating a wound comprising a plasma chamber having:
5 one or more electrodes, a gas supply inlet, a plasma outlet exposed to ambient pressure, and a ignition system operatively connected to said electrodes for providing a non-thermal equilibrium plasma within the plasma chamber; and an aerosol delivery system operable to introduce a bioresorbable material as an aerosol into the plasma, to produce a coating on the wound surface.
- 10 2. A plasma coating device according to claim 1 in which said aerosol delivery system is arranged to provide said aerosol into the plasma chamber.
3. A plasma coating device according to claim 1 in which said aerosol delivery system is arranged to provide said aerosol into a region containing reactive species emanating from said plasma chamber outlet.
- 15 4. A plasma coating device is which said aerosol delivery system is arranged to contain a bioresorbable material pre-cursor either dissolved or dispersed in a carrier liquid.
5. A plasma coating device as claimed in claim 1 wherein said ignition system is arranged to provide power to said plasma at a frequency of at least 100kHz.
6. A plasma coating device as claimed in claim 1 wherein said ignition system is
20 arranged to provide power to said plasma at a frequency of between 100kHz and 500kHz.
7. A plasma coating device as claimed in claim 1 wherein said ignition system is arranged to pulse said plasma.
8. A plasma coating device as claimed in claim 1 further comprising a ground electrode
25 disposed between the plasma chamber outlet and the wound to be treated.
9. A plasma coating device as claimed in claim 1 wherein the plasma is one of a dielectric barrier discharge; an atmospheric pressure glow discharge, a corona plasma or a plasma jet.
10. A plasma coating device as claimed in claim 1 wherein said aerosol delivery system is
30 arranged to supply said aerosol to said wound after a period of treating the wound with only said plasma.

11. A plasma coating device as claimed in claim 1 further comprising means for providing an active compound to said wound in conjunction with said plasma treated bioresorbable material.
12. A plasma coating device as claimed in claim 11 wherein said active compound is
5 either dissolved in the bioresorbable material pre-cursor or introduced separately to the plasma
13. A plasma coating device as claimed in claim 1 further comprising a gas supply arranged to provide a supply of helium, argon, nitrogen or mixtures thereof to said chamber.
- 10 14. A non-thermal equilibrium plasma treated bioresorbable material for use in coating a wound.
15. A material for use in coating a wound as claimed in claim 14 wherein the bioresorbable material is a biopolymer, a biodegradable polymer, a protein or a mixture thereof.
- 15 16. A material for use in coating a wound as claimed in claim 15 comprising a protein including collagen, fibrin or fibronectin; a biopolymer including chitin, hyaluronan, chitosan, alginates or cellulose; or a biodegradable polymer including PLGA, polylactic acid, polycaprolactone or polyglactin.
17. A material for use in coating a wound as claimed in claim 14 comprising one of:
20 blood, blood plasma or a blood constituent.
18. A material for use in coating a wound as claimed in claim 14 further comprising one of a pharmaceutical agent or a biologically active compound or combinations thereof.
19. A material for use in coating a wound as claimed in claim 18 comprising one or more of a drug, enzyme, cell, protein or DNA.
- 25 20. A material for use in coating a wound as claimed in claim 14 further including one or more of anti-cancer drugs, anti-inflammatory drugs, immuno-suppressants, antibiotics, antimicrobials, heparin, a functional protein, a regulatory protein, structural proteins, oligo-peptides, antigenic peptides, nucleic acids, immunogens, glycosaminoglycans.
- 30 21. A material for use in coating a wound as claimed in claim 14 further including one or more of polypeptides, polyglycans, hormones, lipids, interferons, cartilage, therapeutic biologic agents both cellular and synthetically derived, autologous, homologous and allographic and xenographic biologic agents, autologous or homologous, recombinant and synthetic derived blood cells and products containing

antimicrobial or antibiotic agents, bacteriostatic agents, stem cells, stromal cells; fibroblast derived Human Dermal Collagen, matrix proteins, growth factors and cytokines, fibronectin, cells found in loose connective tissue such as endothelial cells, cells found in adipose tissue, macrophages, monocytes, adipocytes, pericytes, reticular
5 cells found in bone marrow stroma or cultured autologous keratinocytes.

22. A method of treating a wound comprising: providing a plasma coating device as claimed in claim 1 and applying a non-thermal equilibrium plasma treated bioresorbable material to coat the wound.

23. A method according to claim 22 wherein the wound comprises a fresh trauma or a
10 burn and wherein the bioresorbable material contains one or more of an antimicrobial compound, an analgesic or vasoconstrictors.

24. A method according to claim 22 wherein the wound is at a haemostasis stage and wherein said bioresorbable material comprises either blood plasma or platelets including one or more of vasoconstrictors, adenosine diphosphate, thrombin,
15 fibrinogen, fibrin, cytokines, chemotactic factors, chemocines or coagulation factors.

25. A method according to claim 22 wherein the wound is at an inflammation stage and wherein said bioresorbable material comprises blood plasma including one or more of neutrophils, monocytes, phagocytes, mast cells, proteolytic enzymes or leukocytes.

26. A method according to claim 22 wherein the wound is at a granulation stage and
20 wherein said bioresorbable material includes one or more of macrophages, Fibroblastic Growth Factor, Epidermal Growth Factor, transforming growth factor beta, extra cellular matrix, fibroblasts or myofibroblasts.

27. A method according to claim 22 wherein the wound is at a contracture stage and wherein said bioresorbable material includes one or more of fibroblasts, collagen,
25 endothelial cells, keratinocytes, angiocytes or neurocytes.

28. A method according to claim 22 wherein the wound is at an epithelisation stage and wherein said bioresorbable material includes one or more of growth factors, fibrin, collagen or fibronectin.

29. A method according to claim 22 comprising remodelling a wound and wherein said
30 bioresorbable material comprises type I collagen.

30. A method according to claim 22 comprising treating a large wound, burn injury or chronic non-healing ulcer and wherein said bioresorbable material comprises cytokines and growth factors.

31. A method according to claim 22 comprising re-generating a cornea and wherein said bioresorbable material comprises cytokines.




Figure 1

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 10/01439

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61L 2/14 (2010.01)

USPC - 427/2.31

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - A61L 2/14 (2010.01)

USPC - 427/2.31

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

A61L 2/00, 2/02, 26/00; A61K 9/00, 9/12; A61B 18/00; A61F 13/00; H05H 1/00, 1/24, 1/26, 1/34
424/400, 443, 445, 446; 602/41, 42, 900, 904

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PubWest (PGPB, USPT, EPAB, JPAB); Google

Search Terms: plasma, glow discharge, dielectric near2 discharge, corona, spray\$, coat\$, deposit\$, wound, non-thermal, equilibrium, cold plasma,

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2007/0029500 A1 (COULOMBE et al.) 08 February 2007 (08.02.2007) Entire document, especially Abstract, para[0010] - para[0011], para[0040] - para[0044], para[0056] - para[0058], para[0087] and FIG. 1.	1-9, 13-15 and 22
Y		10-12, 16-21 and 23-31
Y	US 2008/0237484 A1 (MORFILL et al.) 02 October 2008 (02.10.2008) Entire document, especially Abstract.	10
Y	US 2008/0118734 A1 (GOODWIN et al.) 22 May 2008 (22.05.2008) Entire document, especially Abstract, para[0031] - para[0033] and para[0062] - para[0063].	11-12, 18-21 and 23
Y	US 2008/0199513 A1 (BERETTA et al.) 21 August 2008 (21.08.2008) Abstract, para[0004] - para[0008], para[0135] - para[0136] and para[0229].	16-17 and 24-30
Y	US 2004/0176749 A1 (LOHMANN et al.) 09 September 2004 (09.09.2004) para[0018].	31
T	WO 2010/022871 A1 (MORFILL et al.) 04 March 2010 (04.03.2010) Entire document	1-31

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

05 November 2010 (05.11.2010)

Date of mailing of the international search report

16 NOV 2010

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774